Objective: To investigate the clinical effect of dagaglizin in the adjuvant treatment of chronic heart failure (CHF). Methods: 85 patients with CHF who were admitted to our rest home from June 2022 to May 2024 were selected as the study objects. Patients were divided into control group (n=42) and observation group (n=43) by random number table method. The cardiac function indexes [Left ventricular ejection fraction (LVEF), N-terminal pro-B-type natriuretic peptide (NT-proBNP)], inflammatory indicators [interleukin-6 (IL-6), Tumor necrosis factor-α(TNF-α)], adverse reactions, and the incidence of Major adverse cardiovascular events (MACE) were detected and compared between the two groups. Results: After 6 months of treatment, LVEF and NT-proBNP in both groups were significantly higher than before treatment, and NT-PROBNP was significantly lower than before treatment (P < 0.05). The LVEF and NT-proBNP of the observation group were significantly higher than those of the control group (P < 0.05). After 6 months of treatment, serum IL-6 and TNF-α in both groups were significantly decreased compared with those before treatment (P < 0.05), and serum IL-6 and TNF-α in observation group were significantly lower than those in control group (P < 0.05). During treatment, the incidence of MACE in the observation group was significantly lower than that in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Daglipzin adjuvant treatment of CHF can reduce inflammatory response, improve cardiac function, and reduce the risk of MACE, with good safety.